Publications by authors named "D Schewe"
Central nervous system (CNS) involvement remains a clinical hurdle in treating childhood B-cell precursor acute lymphoblastic leukemia (BCP-ALL). The disease mechanisms of CNS leukemia are primarily investigated using 2-dimensional cell culture and mouse models. Given the variations in cellular identity and architecture between the human and murine CNS, it becomes imperative to seek complementary models to study CNS leukemia.
View Article and Find Full Text PDFAcute lymphoblastic leukemia (ALL) arises from the uncontrolled proliferation of B-cell precursors (BCP-ALL) or T cells (T-ALL). Current treatment protocols obtain high cure rates in children but are based on toxic polychemotherapy. Novel therapies are urgently needed, especially in relapsed/refractory (R/R) disease, high-risk (HR) leukemias and T-ALL, in which immunotherapy approaches remain scarce.
View Article and Find Full Text PDFArticle Synopsis
- CD19-directed immunotherapy is key for treating B-cell precursor acute lymphoblastic leukemia (BCP-ALL), leading to better outcomes and lower toxicity, but challenges like therapy resistance and short remissions persist.
- Researchers tested a new CD19 antibody (CD19-DE) and a modified CD47 antibody (Hu5F9-IgG2σ) to enhance its effectiveness, especially in cases resistant to CD19 treatment.
- The combination therapy showed significant potential in improving therapeutic responses in various BCP-ALL models, indicating it could be a promising option for relapsed and resistant patients.
Objective: The neurobehavioral underpinnings of binge-eating disorder (BED), co-occurring with obesity (OB), are largely unknown. This research project conceptualizes BED as a disorder with dysfunctional emotion regulation (ER) linked with changes in central noradrenaline (NA) transmission and NA-modulated neuronal networks.
Methods: We expect abnormalities in NA activity in both BED and OB, but most pronounced in BED.